How many Canagliflozin clinical trials are there?

128 Canagliflozin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 99 are marked completed.

Are Canagliflozin clinical trials recruiting in 2026?

Yes — 5 Canagliflozin trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.

What conditions is Canagliflozin being studied for?

Canagliflozin is being studied for Healthy, Diabetes Mellitus, Type 2, Type 2 Diabetes Mellitus, Type 2 Diabetes, Obesity and 55 more. The trials are grouped by indication on this page.

What phase is Canagliflozin in?

Canagliflozin clinical trials span 26 Phase 4, 21 Phase 3, 10 Phase 2, 52 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Canagliflozin clinical trials?

The lead sponsor across the most Canagliflozin trials is Janssen Research & Development, LLC, with 47 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Canagliflozin Clinical Trials (2026): 128 Studies for Healthy & Diabetes Mellitus, Type 2

Creator: Hipa.ai Research
Published: 2026-05-08T19:32:12.684Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

128 Canagliflozin clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 36 indications (including Healthy & Diabetes Mellitus, Type 2) and 1,166,824 total planned enrollment. 21 Phase 3 Canagliflozin trials and 10 Phase 2, 26 Phase 4 are listed. 7 Canagliflozin clinical trials are actively recruiting. Most recent activity: NCT06182839 (Mar 2029).

Canagliflozin clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	not yet recruiting	unknown	Total
P1	1	1	50					52
P1/P2			1				1	2
P2	3	2	5					10
P2/P3	1							1
P3			21					21
P4		1	14	2	2	1	6	26
N/A			8		1	1	6	16

Recruiting Canagliflozin clinical trials (7)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06182839	CARe-MRICanagliflozin in Advanced Renal Disease With MRI Endpoints	P2	ESRD, CKD Stage 4, CKD Stage 5	92	May 2024
NCT06913647	CAN-PDEffect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis	P2	ESRD	30	Feb 2026
NCT06528405	ESS-AKDThe Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease	P2	Acute Kidney Injury	264	Nov 2024
NCT06858436	SUPERSGLT2 Inhibitor Utilization Re-perfusion Therapy	P4	Acute Ischemic Stroke From Large Vessel Occlusion	150	Apr 2026
NCT05903703	Canagliflozin With Gemcitabine in Pancreatic Carcinoma	N/A	Pancreatic Cancer	20	Oct 2023
NCT05427084	CANTORSINGCanagliflozin Targeting Vascular Inflammation	P2/P3	Diabetes Type 2	24	Nov 2024
NCT07076823	MSI-HSafety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer	P1	Colorectal Cancer	15	Jul 2025

Canagliflozin clinical trials by indication

Healthy (38)

NCT	Acronym	Phase	Status	Title
NCT02851095	XR	P1	completed	A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
NCT02846506	—	P1	completed	A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
NCT02865668	—	P1	completed	A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
NCT02851212	—	P1	completed	A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
NCT02220218	IR	P1	completed	Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants
NCT02077803	XR	P1	completed	A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
NCT02071368	XR	P1	completed	A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
NCT01877889	—	P1	completed	A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers
+ 30 more, see All trials below.

Diabetes Mellitus, Type 2 (33)

NCT	Acronym	Phase	Status	Title
NCT02891954	—	P1	active not recruiting	Genetics of Response to Canagliflozin
NCT04304261	ESCDP	P3	completed	Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
NCT04796428	GOLDEN-AGE	P4	unknown	GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial
NCT03170518	—	P3	completed	A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
NCT02624908	—	P4	unknown	Canagliflozin-Mealtime Insulin Rescue
NCT03604224	—	N/A	completed	A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
NCT02065791	CREDENCE	P3	completed	Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
NCT03267576	COMETA	P4	completed	An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
+ 25 more, see All trials below.

Type 2 Diabetes Mellitus (11)

NCT	Acronym	Phase	Status	Title
NCT05856578	—	P4	unknown	Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes
NCT06099067	HARRP	N/A	completed	Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
NCT02964585	—	P4	completed	Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
NCT04014192	—	P4	unknown	Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus
NCT02324842	—	N/A	completed	Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
NCT02622113	TA-7284	P4	completed	Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
NCT02227849	TA-7284	P4	completed	Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
NCT02354222	—	P3	completed	Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
+ 3 more, see All trials below.

Type 2 Diabetes (6)

NCT	Acronym	Phase	Status	Title
NCT05507892	—	P2	active not recruiting	Renal Mechanism of SGLT2 Inhibition
NCT05367063	CANA-DIA-FIB	P4	completed	Canagliflozin and Myocardial Fibrosis
NCT05347459	—	N/A	unknown	Cognitive Protective Effect of Newer Antidiabetic Drugs
NCT02653209	TriMaster	P4	completed	TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
NCT02360774	—	P4	completed	Mechanisms of Weight Loss With SGLT2 Inhibition
NCT02142309	AMAZING	P4	unknown	Glycemic Durability After Metformin Failure

Healthy Volunteers (3)

NCT	Acronym	Phase	Status	Title
NCT02404870	SGLT2	P1	completed	Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers
NCT02073227	XR	P1	completed	A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
NCT02065752	XR	P1	completed	A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Polycystic Ovary Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT06256289	—	P4	unknown	Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
NCT04973891	—	P1/P2	completed	CANA/Met in Non-diabetic Women With PCOS

Type 2 Diabetes Mellitus With Complication (2)

NCT	Acronym	Phase	Status	Title
NCT05513729	—	N/A	unknown	Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
NCT05422092	—	N/A	unknown	Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT05090358	—	P2	active not recruiting	Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
NCT04073680	—	P1/P2	unknown	A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Diabetes Mellitus (2)

NCT	Acronym	Phase	Status	Title
NCT04288778	—	P4	completed	A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes
NCT02462421	SGLT2iPGx	P4	terminated	Pharmacogenetics of SGLT2 Inhibitors

Diabetes (2)

NCT	Acronym	Phase	Status	Title
NCT03936010	—	N/A	completed	Replication of the CANVAS Diabetes Trial in Healthcare Claims
NCT03136484	SUSTAIN 8	P3	completed	Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Obesity (2)

NCT	Acronym	Phase	Status	Title
NCT02243202	—	P2	completed	Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
NCT00650806	JNJ-28431754	P2	completed	A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

Acute Ischemic Stroke From Large Vessel Occlusion (1)

NCT	Acronym	Phase	Status	Title
NCT06858436	SUPER	P4	not yet recruiting	SGLT2 Inhibitor Utilization Re-perfusion Therapy

ESRD (1)

NCT	Acronym	Phase	Status	Title
NCT06913647	CAN-PD	P2	recruiting	Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis

Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07076823	MSI-H	P1	recruiting	Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer

Diabetes Mellitus Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT06851962	EPHIC-DIA2	P4	active not recruiting	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Acute Kidney Injury (1)

NCT	Acronym	Phase	Status	Title
NCT06528405	ESS-AKD	P2	recruiting	The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

Diabetes Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT05427084	CANTORSING	P2/P3	recruiting	Canagliflozin Targeting Vascular Inflammation

ESRD, CKD Stage 4, CKD Stage 5 (1)

NCT	Acronym	Phase	Status	Title
NCT06182839	CARe-MRI	P2	recruiting	Canagliflozin in Advanced Renal Disease With MRI Endpoints

Pancreatic Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05903703	—	N/A	not yet recruiting	Canagliflozin With Gemcitabine in Pancreatic Carcinoma

Chronic Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT05364190	The CANA -AHF	P3	completed	Canagliflozin in Patients With Acute Decompansted Heart Failure

PreDiabetes (1)

NCT	Acronym	Phase	Status	Title
NCT05135039	—	N/A	unknown	Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV.

Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT04252287	CHIEF-HF	P3	completed	A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

Fatty Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05764811	—	N/A	completed	SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

Type2 Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT03298009	Canacardia	N/A	withdrawn	Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

Diabetic Nephropathy (1)

NCT	Acronym	Phase	Status	Title
NCT03436693	TA-7284	P3	completed	Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Overweight (1)

NCT	Acronym	Phase	Status	Title
NCT03426956	—	N/A	unknown	Glucose Absorption and Gut Hormone Secretion After Gastric Bypass

Postprandial Hypoglycemia (1)

NCT	Acronym	Phase	Status	Title
NCT04720859	CANA-PHH-RYGB	N/A	unknown	Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)

Type2 Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT03190798	—	P4	withdrawn	Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Heart Failure, Systolic (1)

NCT	Acronym	Phase	Status	Title
NCT02920918	—	P4	completed	Treatment of Diabetes in Patients With Systolic Heart Failure

Type 1 Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT02673138	—	N/A	completed	Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

Diabetes, Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT02597309	I-Can	P4	withdrawn	The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin

Bioequivalence (1)

NCT	Acronym	Phase	Status	Title
NCT02221180	FDC	P1	completed	Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Diabetes Mellitus, Type 1 (1)

NCT	Acronym	Phase	Status	Title
NCT02139943	T1DM	P2	completed	A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Healthy Subjects (1)

NCT	Acronym	Phase	Status	Title
NCT01916863	—	P1	completed	Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Diabetes Mellitus, Type II (1)

NCT	Acronym	Phase	Status	Title
NCT00642278	JNJ-28431754	P2	completed	An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Renal Insufficiency (1)

NCT	Acronym	Phase	Status	Title
NCT01759576	JNJ-28431754	P1	completed	A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

Canagliflozin pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
SUPER	NCT06858436	P4	not yet recruiting	Acute Ischemic Stroke From Large Vessel Occlusion	150	—
EPHIC-DIA2	NCT06851962	P4	active not recruiting	Diabetes Mellitus Type 2	504	—
CANA-DIA-FIB	NCT05367063	P4	completed	Type 2 Diabetes	45	PMID 41735586
GOLDEN-AGE	NCT04796428	P4	unknown	Diabetes Mellitus, Type 2	1,167	—
SGLT2iPGx	NCT02462421	P4	terminated	Diabetes Mellitus	30	PMID 36993363
TriMaster	NCT02653209	P4	completed	Type 2 Diabetes	525	PMID 36477733
COMETA	NCT03267576	P4	completed	Diabetes Mellitus, Type 2	64	—
Can Do	NCT02694263	P4	completed	Diabetes Mellitus, Type 2	25	PMID 37435938
CARAT	NCT02912455	P4	terminated	Diabetes Mellitus, Type 2	16	—
I-Can	NCT02597309	P4	withdrawn	Diabetes, Obesity	0	—
CANVAS-R	NCT01989754	P4	completed	Diabetes Mellitus, Type 2	5,813	PMID 31399845
AMAZING	NCT02142309	P4	unknown	Type 2 Diabetes	450	—
TA-7284	NCT02622113	P4	completed	Type 2 Diabetes Mellitus	139	PMID 29110384
TA-7284	NCT02227849	P4	completed	Type 2 Diabetes Mellitus	71	PMID 29473709
TA-7284	NCT02220920	P4	completed	Type 2 Diabetes Mellitus	146	PMID 27316668
ESCDP	NCT04304261	P3	completed	Diabetes Mellitus, Type 2	100	—
The CANA -AHF	NCT05364190	P3	completed	Chronic Heart Failure	142	—
CHIEF-HF	NCT04252287	P3	completed	Heart Failure	476	PMID 35228753
TA-7284	NCT03436693	P3	completed	Diabetic Nephropathy	308	PMID 35861630
SUSTAIN 8	NCT03136484	P3	completed	Diabetes	788	PMID 31897524
CREDENCE	NCT02065791	P3	completed	Diabetes Mellitus, Type 2	4,401	PMID 33874750
CANVAS	NCT01032629	P3	completed	Diabetes Mellitus, Type 2	4,330	PMID 30591006
CANTATA-SU	NCT00968812	P3	completed	Diabetes Mellitus, Type 2	1,452	PMID 27495291
CARe-MRI	NCT06182839	P2	recruiting	ESRD, CKD Stage 4, CKD Stage 5	92	—
CAN-PD	NCT06913647	P2	recruiting	ESRD	30	—
ESS-AKD	NCT06528405	P2	recruiting	Acute Kidney Injury	264	—
T1DM	NCT02139943	P2	completed	Diabetes Mellitus, Type 1	352	PMID 27899497
JNJ-28431754	NCT00642278	P2	completed	Diabetes Mellitus, Type II	451	PMID 22492586
JNJ-28431754	NCT00650806	P2	completed	Obesity	376	—

Terminated and withdrawn Canagliflozin trials (5)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT02462421terminatedPharmacogenetics of SGLT2 Inhibitors
NCT03190798withdrawnEffects of Canagliflozin on Intravascular Volume and Hemodynamics
NCT02912455terminatedCARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes
NCT03298009withdrawnImpact of a Short-term Treatment With Canagliflozin (Canacardia-HF)
NCT02597309withdrawnThe Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin

All Canagliflozin trials (128)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06182839	CARe-MRI	Canagliflozin in Advanced Renal Disease With MRI Endpoints	P2	recruiting	92	McGill University Health Centre/Research Institute of the McGill University Health Centre	May 2024
NCT06913647	CAN-PD	Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis	P2	recruiting	30	McGill University Health Centre/Research Institute of the McGill University Health Centre	Feb 2026
NCT06528405	ESS-AKD	The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease	P2	recruiting	264	National Taiwan University Hospital	Nov 2024
NCT06858436	SUPER	SGLT2 Inhibitor Utilization Re-perfusion Therapy	P4	not yet recruiting	150	Taichung Veterans General Hospital	Apr 2026
NCT05903703		Canagliflozin With Gemcitabine in Pancreatic Carcinoma	N/A	not yet recruiting	20	Zhang Xiaofeng,MD	Oct 2023
NCT05427084	CANTORSING	Canagliflozin Targeting Vascular Inflammation	P2/P3	recruiting	24	Ottawa Heart Institute Research Corporation	Nov 2024
NCT02891954		Genetics of Response to Canagliflozin	P1	active not recruiting	700	University of Maryland, Baltimore	Sep 2016
NCT05507892		Renal Mechanism of SGLT2 Inhibition	P2	active not recruiting	45	University of Colorado, Denver	Oct 2022
NCT05090358		Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer	P2	active not recruiting	15	Memorial Sloan Kettering Cancer Center	Oct 2021
NCT07076823	MSI-H	Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer	P1	recruiting	15	West China Hospital	Jul 2025
NCT06851962	EPHIC-DIA2	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.	P4	active not recruiting	504	Fundación para la Investigación del Hospital Clínico de Valencia	May 2025
NCT06256289		Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome	P4	unknown	50	Ping Li,MD	Mar 2024
NCT05367063	CANA-DIA-FIB	Canagliflozin and Myocardial Fibrosis	P4	completed	45	Shanghai Zhongshan Hospital	Jan 2022
NCT05135039		Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV.	N/A	unknown	218	xiaolong zhao	Jan 2022
NCT04304261	ESCDP	Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)	P3	completed	100	Third Military Medical University	Jul 2021
NCT05513729		Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease	—	unknown	80	First Affiliated Hospital Xi'an Jiaotong University	Aug 2022
NCT05364190	The CANA -AHF	Canagliflozin in Patients With Acute Decompansted Heart Failure	P3	completed	142	October 6 University	Jun 2022
NCT05422092		Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease	N/A	unknown	80	First Affiliated Hospital Xi'an Jiaotong University	Sep 2022
NCT05856578		Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes	P4	unknown	60	Nanjing First Hospital, Nanjing Medical University	Mar 2022
NCT05347459		Cognitive Protective Effect of Newer Antidiabetic Drugs	—	unknown	100	Alexandria University	Mar 2022
NCT04796428	GOLDEN-AGE	GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial	P4	unknown	1,167	Center for Outcomes Research and Clinical Epidemiology, Italy	Jun 2021
NCT03170518		A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus	P3	completed	171	Janssen Research & Development, LLC	Jul 2017
NCT06099067	HARRP	Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)	—	completed	239,990	AstraZeneca	May 2020
NCT05764811		SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity	N/A	completed	40	National Cheng-Kung University Hospital	Mar 2020
NCT04720859	CANA-PHH-RYGB	Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)	N/A	unknown	40	Hospital Universitari Vall d'Hebron Research Institute	Jan 2018
NCT02624908		Canagliflozin-Mealtime Insulin Rescue	P4	unknown	40	Foundation for Atlanta Veterans Education and Research, Inc.	Jan 2016
NCT04288778		A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes	P4	completed	276	Johnson & Johnson Private Limited	Nov 2020
NCT04973891		CANA/Met in Non-diabetic Women With PCOS	P1/P2	completed	52	Shengjing Hospital	Apr 2021
NCT02462421	SGLT2iPGx	Pharmacogenetics of SGLT2 Inhibitors	P4	terminated	30	University of Maryland, Baltimore	Jun 2015
NCT04073680		A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors	P1/P2	unknown	60	Petra Pharma	Sep 2020
NCT04252287	CHIEF-HF	A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure	P3	completed	476	Janssen Research & Development, LLC	Mar 2020
NCT03936010		Replication of the CANVAS Diabetes Trial in Healthcare Claims	—	completed	152,202	Brigham and Women's Hospital	Sep 2017
NCT02653209	TriMaster	TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.	P4	completed	525	Royal Devon and Exeter NHS Foundation Trust	Nov 2016
NCT03436693	TA-7284	Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy	P3	completed	308	Tanabe Pharma Corporation	Feb 2018
NCT02964585		Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes	P4	completed	34	George Washington University	Nov 2016
NCT04014192		Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus	P4	unknown	40	Peking Union Medical College Hospital	Sep 2019
NCT02404870	SGLT2	Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers	P1	completed	67	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Sep 2014
NCT03604224		A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting	—	completed	178	Johnson & Johnson Private Limited	Sep 2018
NCT03426956		Glucose Absorption and Gut Hormone Secretion After Gastric Bypass	N/A	unknown	10	Hvidovre University Hospital	Feb 2018
NCT02324842		Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients	N/A	completed	45	The University of Texas Health Science Center at San Antonio	Nov 2014
NCT03136484	SUSTAIN 8	Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes	P3	completed	788	Novo Nordisk A/S	Mar 2017
NCT02065791	CREDENCE	Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy	P3	completed	4,401	Janssen Research & Development, LLC	Feb 2014
NCT03267576	COMETA	An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin	P4	completed	64	Janssen Research & Development, LLC	Oct 2017
NCT02920918		Treatment of Diabetes in Patients With Systolic Heart Failure	P4	completed	36	Virginia Commonwealth University	Oct 2016
NCT02694263	Can Do	Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan	P4	completed	25	University of Leicester	Jul 2016
NCT02360774		Mechanisms of Weight Loss With SGLT2 Inhibition	P4	completed	30	Beth Israel Deaconess Medical Center	Feb 2015
NCT03190798		Effects of Canagliflozin on Intravascular Volume and Hemodynamics	P4	withdrawn	0	The University of Texas Health Science Center at San Antonio	Sep 2017
NCT02912455	CARAT	CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes	P4	terminated	16	The Cleveland Clinic	Jan 2017
NCT03298009	Canacardia	Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)	N/A	withdrawn	0	Université de Sherbrooke	May 2018
NCT03492580		A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease	—	completed	714,582	Janssen Research & Development, LLC	Feb 2018
NCT03249506	T2DM	Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)	—	completed	25,358	Janssen Research & Development, LLC	May 2016
NCT02673138		Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion	N/A	completed	10	Yale University	Jan 2016
NCT02597309	I-Can	The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin	P4	withdrawn	0	Joslin Diabetes Center	Nov 2015
NCT01989754	CANVAS-R	A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus	P4	completed	5,813	Janssen Research & Development, LLC	Jan 2014
NCT01032629	CANVAS	CANVAS - CANagliflozin cardioVascular Assessment Study	P3	completed	4,330	Janssen Research & Development, LLC	Dec 2009
NCT02142309	AMAZING	Glycemic Durability After Metformin Failure	P4	unknown	450	University of Campania Luigi Vanvitelli	Oct 2005
NCT02009488	T2DM	Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)	P1	completed	59	Janssen Research & Development, LLC	Sep 2014
NCT02851095	XR	A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants	P1	completed	44	Janssen Research & Development, LLC	Aug 2016
NCT02846506		A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants	P1	completed	44	Janssen Research & Development, LLC	Aug 2016
NCT02865668		A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants	P1	completed	44	Janssen Research & Development, LLC	Aug 2016
NCT02851212		A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants	P1	completed	44	Janssen Research & Development, LLC	Aug 2016
NCT02622113	TA-7284	Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus	P4	completed	139	Tanabe Pharma Corporation	Dec 2014
NCT02000700		A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus	P1	completed	17	Janssen Research & Development, LLC	Mar 2014
NCT02227849	TA-7284	Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus	P4	completed	71	Tanabe Pharma Corporation	Aug 2014
NCT02354222		Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)	P3	completed	154	Tanabe Pharma Corporation	Jan 2015
NCT02220907		Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes	P3	completed	153	Tanabe Pharma Corporation	Aug 2014
NCT02354235		Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)	P3	completed	138	Tanabe Pharma Corporation	Jan 2015
NCT02025907		A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin	P4	completed	218	Janssen Research & Development, LLC	Feb 2014
NCT02220920	TA-7284	Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus	P4	completed	146	Tanabe Pharma Corporation	Aug 2014
NCT02243202		Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants	P2	completed	335	Janssen Research & Development, LLC	Sep 2014
NCT02139943	T1DM	A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)	P2	completed	352	Janssen Research & Development, LLC	May 2014
NCT01939496		Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents	P4	completed	171	Janssen Scientific Affairs, LLC	Oct 2013
NCT01809327		A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise	P3	completed	1,186	Janssen Research & Development, LLC	Jun 2013
NCT02221180	FDC	Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants	P1	completed	2	Janssen Research & Development, LLC	Aug 2014
NCT02220218	IR	Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants	P1	completed	2	Janssen Research & Development, LLC	Aug 2014
NCT02077803	XR	A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants	P1	completed	47	Janssen Research & Development, LLC	Mar 2014
NCT02073227	XR	A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components	P1	completed	52	Janssen Research & Development, LLC	Feb 2014
NCT02071368	XR	A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants	P1	completed	3	Janssen Research & Development, LLC	Feb 2014
NCT02065752	XR	A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components	P1	completed	2	Janssen Research & Development, LLC	Feb 2014
NCT01877889		A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers	P1	completed	60	Janssen-Cilag International NV	Jul 2013
NCT01916863		Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects	P1	completed	25	Lexicon Pharmaceuticals	Aug 2013
NCT01106651		A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus	P3	completed	716	Janssen Research & Development, LLC	Jun 2010
NCT00968812	CANTATA-SU	CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride	P3	completed	1,452	Janssen Research & Development, LLC	Sep 2009
NCT01381900		A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea	P3	completed	678	Janssen Research & Development, LLC	Aug 2011
NCT01665638		Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers	P1	completed	10	Janssen-Cilag International NV	Sep 2012
NCT01707316		A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers	P1	completed	15	Janssen Research & Development, LLC	Jun 2012
NCT01483781		A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus	P1	completed	36	Janssen Research & Development, LLC	Dec 2011
NCT01064414		An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment	P3	completed	272	Janssen Research & Development, LLC	Jun 2010
NCT01106690		The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)	P3	completed	344	Janssen Research & Development, LLC	Jun 2010
NCT01106677		The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)	P3	completed	1,284	Janssen Research & Development, LLC	May 2010
NCT01340664		An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy	P2	completed	279	Janssen Research & Development, LLC	Jul 2011
NCT01106625		The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)	P3	completed	469	Janssen Research & Development, LLC	May 2010
NCT01508182		A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers	P1	completed	64	Janssen Research & Development, LLC	Jan 2012
NCT01508195		A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers	P1	completed	64	Janssen Research & Development, LLC	Jan 2012
NCT01137812		The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)	P3	completed	756	Janssen Research & Development, LLC	Jul 2010
NCT01081834		The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial	P3	completed	678	Janssen Research & Development, LLC	Mar 2010
NCT01463228	FDC	A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers	P1	completed	83	Janssen Research & Development, LLC	Sep 2011
NCT01463774	IR	A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers	P1	completed	74	Janssen Research & Development, LLC	Sep 2011
NCT01454622	FDC	A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers	P1	completed	64	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Sep 2011
NCT01518712	FDC	A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers	P1	completed	64	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Sep 2011
NCT01381887		A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus	P1	completed	37	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Jun 2011
NCT01428284		A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers	P1	completed	14	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Aug 2011
NCT01173549		A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers	P1	completed	26	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Nov 2010
NCT01395927		A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers	P1	completed	14	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Jul 2011
NCT01340677		A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers	P1	completed	24	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	May 2011
NCT01294631		A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers	P1	completed	30	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Mar 2011
NCT01273558		A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus	P1	completed	28	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Jan 2011
NCT01343290		The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers	P1	completed	24	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Apr 2011
NCT01286103		A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers	P1	completed	34	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Jan 2011
NCT01718652	JNJ-28431754	A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers	P1	completed	18	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Feb 2011
NCT01281579		A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers	P1	completed	27	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Jan 2011
NCT01186588		A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function	P1	completed	24	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Aug 2010
NCT01273571		A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers	P1	completed	18	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Dec 2010
NCT01195324		A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers	P1	completed	14	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Sep 2010
NCT01128985		A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus	P1	completed	39	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Mar 2010
NCT01157000		A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers	P1	completed	9	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	May 2010
NCT01714206	JNJ-28431754	A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.	P1	completed	18	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Jun 2009
NCT00642278	JNJ-28431754	An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes	P2	completed	451	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Apr 2008
NCT01759576	JNJ-28431754	A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function	P1	completed	40	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Mar 2008
NCT01821027	JNJ-28431754	A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers	P1	completed	22	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Aug 2008
NCT01748526	JNJ-28431754	A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers	P1	completed	16	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Aug 2008
NCT01733108	JNJ-28431754	A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers	P1	completed	29	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Jul 2008
NCT01787357	JNJ-28431754	A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)	P1	completed	60	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Jun 2008
NCT00650806	JNJ-28431754	A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes	P2	completed	376	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	May 2008
NCT01714193	JNJ-28431754	A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers	P1	completed	30	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Feb 2008
NCT01756404	JNJ-28431754	Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers	P1	completed	80	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Jun 2007
NCT01756417	JNJ-28431754	A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers	P1	completed	18	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Oct 2007
NCT01791231	JNJ-28431754	A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers	P1	completed	6	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Aug 2007

Canagliflozin clinical trials: frequently asked questions

How many Canagliflozin clinical trials are there?: 128 Canagliflozin clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 99 are marked completed.
Are Canagliflozin clinical trials recruiting in 2026?: Yes — 5 Canagliflozin trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
What conditions is Canagliflozin being studied for?: Canagliflozin is being studied for Healthy, Diabetes Mellitus, Type 2, Type 2 Diabetes Mellitus, Type 2 Diabetes, Obesity and 55 more. The trials are grouped by indication on this page.
What phase is Canagliflozin in?: Canagliflozin clinical trials span 26 Phase 4, 21 Phase 3, 10 Phase 2, 52 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Canagliflozin clinical trials?: The lead sponsor across the most Canagliflozin trials is Janssen Research & Development, LLC, with 47 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Canagliflozinas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Canagliflozin overview Canagliflozin evidence & publications